Secure shopping
Healthcare and pharma
The Pharma & Healthcare industry is of vital importance for human and economic development, providing a wide range of goods and services relevant to the promotion of health at all stages in the healthcare process – from prevention and treatment to rehabilitation and palliative care. It is one of the fastest-growing industries, supported by profound demographic changes, the rising incidence of non-communicable diseases, and surging per capita health spending in both developed and emerging markets. The industry is also one of the major innovators, with increasing expenditures on development of new molecules, biotechnology and adoption of new technologies that provide advanced healthcare and ensure the longevity of the population.
The Pharma & Healthcare industry comprises the manufacture of pharmaceuticals for human and veterinary use, medical equipment and related supplies. It also includes providers of ambulatory health services, medical and diagnostic laboratories, hospitals, and nursing and residential care facilities.
With 1.4bn population each as of 2017, India and China are the most numerous countries out of the six forming the focus of this report. However, the two countries differ widely in terms of per capita GDP, with that of China being more than twice that ...
View more details
In the third quarter of 2018, China’s pharmaceutical and medicine production declined by 28.5% y/y to 573,000 tonnes, In 2018, many pharmaceutical producers were affected by the ongoing reform for new chemical drugs classification system, and ...
View more details
The third quarter of 2018 witnessed a continuous growth of China’s healthcare sector, mostly driven by the online healthcare segment. The growth was attributed to increasing demand for quality healthcare, stimulated by the country’s ...
View more details
In the second quarter of 2018, China’s pharmaceutical and medicine production declined by 21.1% y/y to 749,000 tonnes, while their sales volume dropped by 22.7% y/y to 753,000 tonnes. This can be linked with the more stringent environmental ...
View more details
The second quarter of 2018 witnessed a continuous growth of China’s healthcare sector. The growth was attributed to increasing demand for quality healthcare, stimulated by the country’s strong economic performance, rising incomes, ...
View more details
The first quarter of 2018 witnessed a continuous growth of China’s healthcare sector, stimulated by government policies and regulations. The country’s total spending on health and family planning reached RMB 442.6bn, up by 7.8% ...
View more details
In Q4 2017, the government expenditure on health and family planning was RMB 276.7bn, representing a decrease of 7.5% y/y. Nevertheless, the healthcare expenditure in urban area was RMB 453.9bn, up by 2.8% y/y. For the whole year 2017, the government ...
View more details
China is the world’s second largest pharmaceutical market after the US and the largest producer and exporter of active pharmaceutical ingredients (APIs) globally. Since it is the world’s most populous country, with a large share of ageing ...
View more details
In the first two months of Q4 of 2017, the sales revenue of China’s pharmaceutical manufacturing sector went down by 17.8% y/y to RMB 445bn, as a result of the government’s tightening control over drug prices and distribution costs. ...
View more details
In Q3 2017 China continued to implement healthcare reforms which resulted in further development and growth of the sector. According to a health management summit held in Beijing in late 2017, the country’s healthcare market will reach RMB 4 ...
View more details